msk-da01
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started May 3, 2021 (NCT04802733)
Timeline
Indications
Studied for
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314657 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06944522 | Phase 3 | Jun 17, 2025 | Bayer, BlueRock Therapeutics |
| NCT04802733 | Phase 1 | May 3, 2021 | BlueRock Therapeutics, Memorial Sloan-Kettering Cancer Center |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BlueRock Therapeutics | For profit | 2 | 2 | 2 | 2021 |
| Bayer | For profit | 1 | 0 | 1 | 2025 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1